Nagaoka Satoshi, Nakamura Atsushi, Shibata Haruhiko, Kanamaru Yoshihiro
Department of Applied Life Science, Faculty of Applied Biological Sciences, Gifu University, Gifu, Japan.
Biosci Biotechnol Biochem. 2010;74(8):1738-41. doi: 10.1271/bbb.100338. Epub 2010 Aug 7.
This study was designed to identify a novel peptide derived from soybean protein that induces inhibition of cholesterol absorption in vivo. VAWWMY (Val-Ala-Trp-Trp-Met-Tyr, designated soystatin) had a significantly greater ability to bind bile acid than soybean protein peptic hydrolysate (SPH) or casein tryptic hydrolysate (CTH). Surprisingly, the bile-acid binding ability of VAWWMY was almost as strong as that of the hypocholesterolemic medicine cholestyramine. The micellar solubility of cholesterol was significantly lower in the presence of VAWWMY than in that of SPH or CTH. We found that soystatin derived from soybean glycinin acted as an inhibitor of cholesterol absorption in vivo.
本研究旨在鉴定一种源自大豆蛋白的新型肽，该肽可在体内诱导胆固醇吸收的抑制作用。VAWWMY（缬氨酸-丙氨酸-色氨酸-色氨酸-甲硫氨酸-酪氨酸，命名为大豆抑素）与大豆蛋白酶解物（SPH）或酪蛋白胰蛋白酶解物（CTH）相比，具有显著更强的结合胆汁酸的能力。令人惊讶的是，VAWWMY的胆汁酸结合能力几乎与降胆固醇药物消胆胺一样强。在存在VAWWMY的情况下，胆固醇的胶束溶解度显著低于SPH或CTH。我们发现源自大豆球蛋白的大豆抑素在体内充当胆固醇吸收的抑制剂。
